Journal Reviews

Orbit journal cover

Tocilizumab in Graves’ orbitopathy

2 February 2024 | | Oculoplastics, Orbit | Graves’ orbitopathy, Tocilizumab, corticosteroid

This prospective European study looks at the response to tocilizumab in corticosteroid-resistant disease. Tocilizumab (TCZ) is a monoclonal antibody that competitively inhibits IL-6 binding to its receptor. Unlike teprotumumab, the advantage of TCZ is that it is already used within...